Recent Company News

• 10:12 PM ET Aug 20, 2025
  

  RBC Capital Markets transfers ALM.SM, BIOA.B.SS, FYB.GR, others

• 05:05 AM ET Aug 08, 2025
  

  Shanghai Junshi Biosciences's new indication application for toripalimab injection JS001 accepted by NMPA (HK$29.16, 0.00)

• 06:47 AM ET Aug 07, 2025
  

  Quick Take - Hikma Pharmaceuticals shares trading lower after mixed H1 results; margin dynamics in Injectables causes some concerns (1748.0000p, -136)

• 04:14 AM ET Aug 07, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (130 total)

• 04:07 AM ET Aug 07, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:19 AM ET Aug 07, 2025
  

  StreetAccount Metrics Recap - Hikma Pharmaceuticals H1 Earnings (1884.0000p, 0)

• 02:12 AM ET Aug 07, 2025
  

  Hikma Pharmaceuticals reports H1 EPS $1.22 vs FactSet $1.13 [2 est, $1.12-1.13] (1884.0000p, 0)

• 06:39 AM ET Aug 06, 2025
  

  StreetAccount Consensus Metrics Preview - Hikma Pharmaceuticals H1 Earnings (1913.0000p, -3)

• 08:12 PM ET Jul 30, 2025
  

  Celltrion reports 3-year clinical results of Vegzelma; reaffirms efficacy and safety (pre-South Korean open) (KRW 180100.0000, 0)

• 11:00 PM ET Jul 20, 2025
  

  Sun Pharmaceutical Industries phase 3 clinical studies evaluating Tildrakizumab 100 mg (ILUMYA) in active psoriatic arthritis meets primary endpoint (INR 1693.25, 0.00)